Seeking Alpha

Novartis walks away from blood vessel dilating drug

  • Privately-held Proteon Therapeutics is on its own to proceed into phase 3 clinicals with PRT-201 after negotiations with Novartis (NVS) fail to bear fruit. The parties could not agree on an acquisition price despite an earlier agreement specifying the right to invest up to $550M based on a successful outcome of the phase 2 trial which, indeed, happened.
  • The drug is a synthetic enzyme that Proteon positions as follow-on therapy for patients who undergo vascular access surgery.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector